Quote:

---

Big week for Alzheimer’s data

Anti-amyloid drugs are once again in the spotlight as the leading players take their data to the stage of a buzzy Alzheimer’s conference. Topping the bill: Researchers still have key questions about Eisai’s investigational Alzheimer’s drug lecanemab following the publication of more Phase III data. While Eisai and partners at Biogen touted a reduction in cognitive decline, the relative lack of new information left experts asking for more. Lilly dropped a first cut of data from a trial pitting donanemab directly against Biogen’s Aduhelm, suggesting it cleared more amyloid early than the controversial approved drug, although it’s unclear what that means. Out of the running for now, Roche spelled out the disappointing data on gantenerumab, which failed a Phase III and (in keeping with the hypothesis) reduced less amyloid than expected.

---